EGFR and prostate cancer: Interestingly, it was found that compounds 30 and 31 impaired the growth of metastatic castration-resistant prostate cancer (mCRPC), a lethal form of prostate cancer, thanks to their ability to target and rearrange into a G4 a region within the promoter of epidermal growth factor receptor (EGFR), reducing the receptor production [63].